Market Overview:
The global generic drugs market reached a value of US$ 320 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 482.5 Billion by 2027, exhibiting at a CAGR of 7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic drugs are bioequivalent of branded medicines with the same active ingredients and equivalent therapeutic effects. They also have similar dosages, risks, consequences, side effects, strengths, intended use, and route of administration. They are relatively less expensive than branded drugs, as the production does not require extensive research. Besides this, the production of these drugs does not involve the repetition of clinical and animal studies to measure the effectiveness and safety of the medicine. As a result, generic drugs are gaining immense traction across the globe.
Generic Drugs Market Trends:
The growing global geriatric population and the rising occurrence of chronic medical disorders, such as cancer, diabetes, and cardiovascular diseases, represent one of the key factors positively influencing the market. In addition, changing dietary patterns and hectic schedules of individuals are leading to various conditions, which, in turn, is catalyzing the demand for generic drugs worldwide. Along with this, increasing efforts by governments of various countries to reduce healthcare costs and promote the manufacturing and uptake of generics are contributing to the market growth. They are also encouraging key players to introduce effective generic drugs and provide easy availability. Apart from this, the low production cost of generic medicines is creating a positive outlook for the market. Additionally, the expansion of the pharma companies and medical stores across the globe is further augmenting the market growth. Furthermore, the rising focus of leading manufacturers on partnership strategies to launch new products is propelling the market growth. Moreover, increasing investments in extensive research and development (R&D) activities and technological advancements in medicine formulation are anticipated to drive the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global generic drugs market, along with forecasts at the global and country-level from 2022-2027. Our report has categorized the market based on therapy area, drug delivery, and distribution channel.
Breakup by Therapy Area:
- Central Nervous System
- Cardiovascular
- Dermatology
- Genitourinary/Hormonal
- Respiratory
- Rheumatology
- Diabetes
- Oncology
- Others
The central nervous system (CNS) represents the leading therapy area due to the rising prevalence of brain and spinal cord ailments across the globe.
Breakup by Drug Delivery:
- Oral
- Injectables
- Dermal/Topical
- Inhalers
Oral medicines are the most preferred form of drug delivery due to their convenient administration, which requires minimal to no medical assistance.
Breakup by Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
Presently, the majority of generic drugs are distributed through retail pharmacy stores as most generic medications are over-the-counter (OTC) medicines and require no prescription.
Breakup by Region:
- United States
- China
- Brazil
- Germany
- France
- India
- United Kingdom
- Japan
- Canada
- Italy
- Others
The United States exhibits a clear dominance in the market on account of numerous initiatives undertaken by governing authorities to improve generic drug manufacturing and access in the country.
Competitive Landscape:
The market is fragmented in nature with the presence of various small and large manufacturers. Some of the leading players operating in the market include Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited, and Aspen Pharmacare Holdings Limited.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Therapy Area, Drug Delivery, Distribution Channel, Country |
| Countries Covered |
United States, China, Brazil, Germany, France, India, United Kingdom, Japan, Canada, Italy, Others |
| Companies Covered |
Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited and Aspen Pharmacare Holdings Limited |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Generic Drugs Industry
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Country
5.5 Market Breakup by Therapy Area
5.6 Market Breakup by Drug Delivery
5.7 Market Breakup by Distribution Channel
5.8 Market Forecast
5.9 SWOT Analysis
5.9.1 Overview
5.9.2 Strengths
5.9.3 Weaknesses
5.9.4 Opportunities
5.9.5 Threats
5.10 Value Chain Analysis
5.10.1 Research and Development
5.10.2 Manufacturing
5.10.3 Marketing and Distribution
5.11 Porter’s Five Forces Analysis
5.11.1 Overview
5.11.2 Bargaining Power of Buyers
5.11.3 Bargaining Power of Suppliers
5.11.4 Degree of Competition
5.11.5 Threat of New Entrants
5.11.6 Threat of Substitutes
5.12 Regulations in the Generic Industry
5.13 Key Market Drivers and Success Factors
6 Performance of Key Countries
6.1 United States
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 China
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Brazil
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Germany
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 France
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 India
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 United Kingdom
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Japan
6.8.1 Market Trends
6.8.2 Market Forecast
6.9 Canada
6.9.1 Market Trends
6.9.2 Market Forecast
6.10 Italy
6.10.1 Market Trends
6.10.2 Market Forecast
6.11 Others
6.11.1 Market Trends
6.11.2 Market Forecast
7 Market Breakup by Therapy Area
7.1 Central Nervous System
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Cardiovascular
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Dermatology
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Genitourinary/Hormonal
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Respiratory
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Rheumatology
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Diabetes
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 Oncology
7.8.1 Market Trends
7.8.2 Market Forecast
7.9 Others
7.9.1 Market Trends
7.9.2 Market Forecast
8 Market Breakup by Drug Delivery
8.1 Oral
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Injectables
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Dermal/Topical
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Inhalers
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Retail Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Hospital Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
10 Competitive Landscape
10.1 Market Structure
10.2 Market Breakup by Key Players
10.3 Key Player Profiles
10.3.1 Teva Pharmaceuticals Industries Ltd.
10.3.2 Mylan N.V.
10.3.3 Novartis AG
10.3.4 Pfizer Inc.
10.3.5 Sun Pharmaceutical Industries Ltd.
10.3.6 Fresenius SE & Co.
10.3.7 Lupin Limited
10.3.8 Endo Pharmaceuticals Inc.
10.3.9 Aurobindo Pharma Limited
10.3.10 Aspen Pharmacare Holdings Limited
11 Generic Drugs Manufacturing Process
11.1 Product Overview
11.2 Detailed Process Flow (Tablets)
11.3 Detailed Process Flow (Injectable)
11.4 Various Types of Unit Operations Involved
11.5 Mass Balance and Raw Material Requirements
12 Project Details, Requirements and Costs Involved
12.1 Land Requirements and Expenditures
12.2 Construction Requirements and Expenditures
12.3 Plant Machinery
12.4 Machinery Pictures
12.5 Raw Material Requirements and Expenditures
12.6 Packaging Requirements and Expenditures
12.7 Transportation Requirements and Expenditures
12.8 Utility Requirements and Expenditures
12.9 Manpower Requirements and Expenditures
12.10 Other Capital Investments
13 Loans and Financial Assistance
14 Project Economics
14.1 Capital Cost of the Project
14.2 Techno-Economic Parameters
14.3 Product Pricing and Margins Across Various Levels of the Supply Chain
14.4 Taxation and Depreciation
14.5 Income Projections
14.6 Expenditure Projections
14.7 Financial Analysis
14.8 Profit Analysis
List of Figure
Figure 1: Global: Generic Drugs Market: Major Drivers and Challenges
Figure 2: Global: Generic Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Generic Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Generic Drugs Market: Breakup by Country (in %), 2021
Figure 5: Global: Generic Drugs Market: Breakup by Therapy Area (in %), 2021
Figure 6: Global: Generic Drugs Market: Breakup by Drug Delivery (in %), 2021
Figure 7: Global: Generic Drugs Market: Breakup by Distribution Channel (in %), 2021
Figure 8: Global: Generic Drugs Industry: SWOT Analysis
Figure 9: Global: Generic Drugs Industry: Value Chain Analysis
Figure 10: Global: Generic Drugs Industry: Porter’s Five Forces Analysis
Figure 11: USA: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 12: USA: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 13: China: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 14: China: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 15: Brazil: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 16: Brazil: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 17: Germany: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 18: Germany: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 19: France: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 20: France: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 21: India: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 22: India: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 23: United Kingdom: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 24: United Kingdom: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 25: Japan: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 26: Japan: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 27: Canada: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 28: Canada: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 29: Italy: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 30: Italy: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 31: Others: Generic Drugs Market (in Million US$), 2016 & 2021
Figure 32: Others: Generic Drugs Market Forecast (in Million US$), 2022-2027
Figure 33: Global: Generic Drugs Market: Oral (in Million US$), 2016 & 2021
Figure 34: Global: Generic Drugs Market Forecast: Oral (in Million US$), 2022-2027
Figure 35: Global: Generic Drugs Market: Injectables (in Million US$), 2016 & 2021
Figure 36: Global: Generic Drugs Market Forecast: Injectables (in Million US$), 2022-2027
Figure 37: Global: Generic Drugs Market: Dermal/Topical (in Million US$), 2016 & 2021
Figure 38: Global: Generic Drugs Market Forecast: Dermal/Topical (in Million US$), 2022-2027
Figure 39: Global: Generic Drugs Market: Inhalers (in Million US$), 2016 & 2021
Figure 40: Global: Generic Drugs Market Forecast: Inhalers (in Million US$), 2022-2027
Figure 41: Global: Generic Drugs Market: Central Nervous System (in Million US$), 2016 & 2021
Figure 42: Global: Generic Drugs Market Forecast: Central Nervous System (in Million US$), 2022-2027
Figure 43: Global: Generic Drugs Market: Cardiovascular (in Million US$), 2016 & 2021
Figure 44: Global: Generic Drugs Market Forecast: Cardiovascular (in Million US$), 2022-2027
Figure 45: Global: Generic Drugs Market: Dermatology (in Million US$), 2016 & 2021
Figure 46: Global: Generic Drugs Market Forecast: Dermatology (in Million US$), 2022-2027
Figure 47: Global: Generic Drugs Market: Genitourinary/Hormonal (in Million US$), 2016 & 2021
Figure 48: Global: Generic Drugs Market Forecast: Genitourinary/Hormonal (in Million US$), 2022-2027
Figure 49: Global: Generic Drugs Market: Respiratory (in Million US$), 2016 & 2021
Figure 50: Global: Generic Drugs Market Forecast: Respiratory (in Million US$), 2022-2027
Figure 51: Global: Generic Drugs Market: Rheumatology (in Million US$), 2016 & 2021
Figure 52: Global: Generic Drugs Market Forecast: Rheumatology (in Million US$), 2022-2027
Figure 53: Global: Generic Drugs Market: Diabetes (in Million US$), 2016 & 2021
Figure 54: Global: Generic Drugs Market Forecast: Diabetes (in Million US$), 2022-2027
Figure 55: Global: Generic Drugs Market: Oncology (in Million US$), 2016 & 2021
Figure 56: Global: Generic Drugs Market Forecast: Oncology (in Million US$), 2022-2027
Figure 57: Global: Generic Drugs Market: Other Therapy Areas (in Million US$), 2016 & 2021
Figure 58: Global: Generic Drugs Market Forecast: Other Therapy Areas (in Million US$), 2022-2027
Figure 59: Global: Generic Drugs Market: Retail Pharmacies (in Million US$), 2016 & 2021
Figure 60: Global: Generic Drugs Market Forecast: Retail Pharmacies (in Million US$), 2022-2027
Figure 61: Global: Generic Drugs Market: Hospital Pharmacies (in Million US$), 2016 & 2021
Figure 62: Global: Generic Drugs Market Forecast: Hospital Pharmacies (in Million US$), 2022-2027
Figure 63: Generic Drugs Industry: Profit Margins at Various Levels of the Supply Chain
Figure 64: Generic Drugs Manufacturing: Production Cost Breakup (in %)
Figure 65: Generic Drugs Manufacturing: Detailed Process Flow
Figure 66: Generic Drugs Manufacturing Process: Conversion Rate of Feedstocks
Figure 67: Generic Drugs Manufacturing: Proposed Plant Layout
Figure 68: Generic Drugs Manufacturing Plant: Breakup of Capital Costs (in %)
List of Table
Table 1: Global: Generic Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Generic Drugs Market Forecast: Breakup by Country (in Million US$), 2022-2027
Table 3: Global: Generic Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2022-2027
Table 4: Global: Generic Drugs Market Forecast: Breakup by Drug Delivery (in Million US$), 2022-2027
Table 5: Global: Generic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 6: Generic Drugs Market: Competitive Structure
Table 7: Generic Drugs Market: Key Players
Table 8: Generic Drugs Manufacturing Plant: Costs Related to Land and Site Development (in US$)
Table 9: Generic Drugs Manufacturing Plant: Costs Related to Civil Works (in US$)
Table 10: Generic Drugs Manufacturing Plant: Costs Related to Machinery Unit (in US$)
Table 11: Generic Drugs Manufacturing Plant: Raw Material Requirements
Table 12: Generic Drugs Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
Table 13: Generic Drugs Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
Table 14: Details of Financial Assistance Offered by Financial Institutions
Table 15: Generic Drugs Manufacturing Plant: Capital Costs (in US$)
Table 16: Generic Drugs Manufacturing Plant: Techno-Economic Parameters
Table 17: Generic Drugs Manufacturing Plant: Taxation and Depreciation (in US$)
Table 18: Generic Drugs Manufacturing Plant: Income Projections (in US$)
Table 19: Generic Drugs Manufacturing Plant: Expenditure Projections (in US$)
Table 20: Generic Drugs Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability (in US$)
Table 21: Generic Drugs Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability (in US$)
Table 22: Generic Drugs Manufacturing Plant: Profit and Loss Account (in US$)